Therapeutics targeting persistent inflammation in chronic kidney disease

Translational Research

Volumn 167, Issue 1, 2016, Pages 204-213

  Machowska, Anna ^a   Carrero, Juan Jesus ^a   Lindholm, Bengt ^a   Stenvinkel, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; BARDOXOLONE; C REACTIVE PROTEIN; CANAKINUMAB; CYTOKINE; CYTOKINE RECEPTOR ANTAGONIST; ERYTHROPOIETIN; FRUCTOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; METHOTREXATE; PENTOXIFYLLINE; PENTRAXIN 3; RAMIPRIL; VITAMIN D; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER;

ANTIINFLAMMATORY ACTIVITY; CHRONIC KIDNEY DISEASE; DEPRESSION; FAT INTAKE; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; INFLAMMATION; INTESTINE FLORA; LIFESTYLE MODIFICATION; OXIDATIVE STRESS; PERIODONTAL DISEASE; PHYSICAL ACTIVITY; PLEIOTROPY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; CHRONIC KIDNEY FAILURE; COMPLICATION;

ANTI-INFLAMMATORY AGENTS; BIOMARKERS; HUMANS; INFLAMMATION; RENAL INSUFFICIENCY, CHRONIC;

EID: 84952639861     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.06.012     Document Type: Review

References (90)

1. P. Stenvinkel Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease J Intern Med 268 2010 456 467
2. P. Stenvinkel, and T.E. Larsson Chronic kidney disease: a clinical model of premature aging Am J Kidney Dis 62 2013 339 351
3. J.P. Kooman, P. Kotanko, A.M. Schols, P.G. Shiels, and P. Stenvinkel Chronic kidney disease and premature ageing Nat Rev Nephrol 10 2014 732 742
4. J.J. Carrero, and P. Stenvinkel Inflammation in end-stage renal disease-what have we learned in 10 years? Semin Dial 23 2010 498 509
5. J.S. Hiramoto, R. Katz, C.A. Peralta, and et al. Inflammation and coagulation markers and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA) Am J Kidney Dis 60 2012 225 232
6. M.A. Pegues, M.A. McCrory, A. Zarjou, and A.J. Szalai C-reactive protein exacerbates renal ischemia-reperfusion injury Am J Physiol Renal Physiol 304 2013 F1358 F1365
7. J.J. Carrero, M.I. Yilmaz, B. Lindholm, and P. Stenvinkel Cytokine dysregulation in chronic kidney disease: how can we treat it? Blood Purif 26 2008 291 299
8. C.L. Meuwese, P. Stenvinkel, F.W. Dekker, and J.J. Carrero Monitoring of inflammation in patients on dialysis: forewarned is forearmed Nat Rev Nephrol 7 2011 166 176
9. C.L. Meuwese, S. Snaedal, N. Halbesma, and et al. Trimestral variations of C-reactive protein, interleukin-6 and tumour necrosis factor-alpha are similarly associated with survival in haemodialysis patients Nephrol Dial Transplant 26 2011 1313 1318
10. P. Stenvinkel, O. Heimburger, F. Paultre, and et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure Kidney Int 55 1999 1899 1911
11. O.M. Akchurin, and F. Kaskel Update on inflammation in chronic kidney disease Blood Purif 39 2015 84 92
12. T. Miyamoto, J.J. Carrero, and P. Stenvinkel Inflammation as a risk factor and target for therapy in chronic kidney disease Curr Opin Nephrol Hypertens 20 2011 662 668
13. S. Kato, M. Chmielewski, H. Honda, and et al. Aspects of immune dysfunction in end-stage renal disease Clin J Am Soc Nephrol 3 2008 1526 1533
14. R. Pecoits-Filho, O. Heimburger, P. Barany, and et al. Associations between circulating inflammatory markers and residual renal function in CRF patients Am J Kidney Dis 41 2003 1212 1218
15. M.I. Yilmaz, Y. Solak, M. Saglam, and et al. The relationship between IL-10 levels and cardiovascular events in patients with CKD Clin J Am Soc Nephrol 9 2014 1207 1216
16. J. Gupta, N. Mitra, P.A. Kanetsky, and et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC Clin J Am Soc Nephrol 7 2012 1938 1946
17. M.I. Yilmaz, P. Stenvinkel, A. Sonmez, and et al. Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes Nephrol Dial Transplant 26 2011 3537 3543
18. M.I. Yilmaz, A. Sonmez, A. Ortiz, and et al. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes Clin J Am Soc Nephrol 6 2011 785 792
19. M. Tong, J.J. Carrero, A.R. Qureshi, and et al. Plasma pentraxin 3 in patients with chronic kidney disease: associations with renal function, protein-energy wasting, cardiovascular disease, and mortality Clin J Am Soc Nephrol 2 2007 889 897
20. M. Boehme, F. Kaehne, A. Kuehne, and et al. Pentraxin 3 is elevated in haemodialysis patients and is associated with cardiovascular disease Nephrol Dial Transplant 22 2007 2224 2229
21. P. Stenvinkel, M. Ketteler, R.J. Johnson, and et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly Kidney Int 67 2005 1216 1233
22. M.E. Suliman, O. Heimburger, P. Barany, and et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy J Am Soc Nephrol 14 2003 1614 1622
23. E. Dounousi, E. Papavasiliou, A. Makedou, and et al. Oxidative stress is progressively enhanced with advancing stages of CKD Am J Kidney Dis 48 2006 752 760
24. C.M. Avesani, J.J. Carrero, J. Axelsson, A.R. Qureshi, B. Lindholm, and P. Stenvinkel Inflammation and wasting in chronic kidney disease: partners in crime Kidney Int 70 2006 S8 S13
25. J.M. Lopez-Gomez, I. Perez-Flores, R. Jofre, and et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance J Am Soc Nephrol 15 2004 2494 2501
26. J.J. Carrero, and P. Stenvinkel Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal Clin J Am Soc Nephrol 4 Suppl 1 2009 S49 S55
27. C. Castaneda, P.L. Gordon, R.C. Parker, K.L. Uhlin, R. Roubenoff, and A.S. Levey Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease Am J Kidney Dis 43 2004 607 616
28. B.S. Cheema, H. Abas, B.C. Smith, and et al. Effect of resistance training during hemodialysis on circulating cytokines: a randomized controlled trial Eur J Appl Physiol 111 2011 1437 1445
29. G. Cobo, P. Gallar, T. Gama-Axelsson, and et al. Clinical determinants of reduced physical activity in hemodialysis and peritoneal dialysis patients J Nephrol 28 4 2015 503 510
30. J.L. Viana, G.C. Kosmadakis, E.L. Watson, and et al. Evidence for anti-inflammatory effects of exercise in CKD J Am Soc Nephrol 25 2014 2121 2130
31. D. Wuerth, S.H. Finkelstein, and F.O. Finkelstein The identification and treatment of depression in patients maintained on dialysis Semin Dial 18 2005 142 146
32. P.L. Kimmel, R.A. Peterson, K.L. Weihs, and et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients Kidney Int 57 2000 2093 2098
33. R.K. Riezebos, K.J. Nauta, A. Honig, F.W. Dekker, and C.E. Siegert The association of depressive symptoms with survival in a Dutch cohort of patients with end-stage renal disease Nephrol Dial Transplant 25 2010 231 236
34. G.J. Ko, M.G. Kim, Y.M. Yu, S.K. Jo, W.Y. Cho, and H.K. Kim Association between depression symptoms with inflammation and cardiovascular risk factors in patients undergoing peritoneal dialysis Nephron Clin Pract 116 2010 c29 c35
35. K.C. Hung, C.C. Wu, H.S. Chen, and et al. Serum IL-6, albumin and co-morbidities are closely correlated with symptoms of depression in patients on maintenance haemodialysis Nephrol Dial Transplant 26 2011 658 664
36. M. Taraz, M.R. Khatami, S. Dashti-Khavidaki, and et al. Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: results of a randomized double-blind, placebo-controlled clinical trial Int Immunopharmacol 17 2013 917 923
37. A. Gharekhani, M.R. Khatami, S. Dashti-Khavidaki, and et al. The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial Eur J Clin Pharmacol 70 2014 655 665
38. H.Y. Chen, I.C. Cheng, Y.J. Pan, and et al. Cognitive-behavioral therapy for sleep disturbance decreases inflammatory cytokines and oxidative stress in hemodialysis patients Kidney Int 80 2011 415 422
39. G. Ismail, H.T. Dumitriu, A.S. Dumitriu, and F.B. Ismail Periodontal disease: a covert source of inflammation in chronic kidney disease patients Int J Nephrol 2013 2013 515796
40. H. Akar, G.C. Akar, J.J. Carrero, P. Stenvinkel, and B. Lindholm Systemic consequences of poor oral health in chronic kidney disease patients Clin J Am Soc Nephrol 6 2011 218 226
41. J.J. Carrero, P. Stenvinkel, L. Cuppari, and et al. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM) J Ren Nutr 23 2013 77 90
42. J.J. Carrero, A.R. Qureshi, J. Axelsson, and et al. Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite Am J Clin Nutr 85 2007 695 701
43. G.J. Linden, K. McClean, I. Young, A. Evans, and F. Kee Persistently raised C-reactive protein levels are associated with advanced periodontal disease J Clin Periodontol 35 2008 741 747
44. P. Fanti, R. Asmis, T.J. Stephenson, B.P. Sawaya, and A.A. Franke Positive effect of dietary soy in ESRD patients with systemic inflammation-correlation between blood levels of the soy isoflavones and the acute-phase reactants Nephrol Dial Transpl 21 2006 2239 2246
45. F.K. Yazdi, N. Karimi, M. Rasouli, and J. Roozbeh Effect of nonsurgical periodontal treatment on C-reactive protein levels in maintenance hemodialysis patients Ren Fail 35 2013 711 717
46. H. Xu, P. Sjogren, J. Arnlov, and et al. A proinflammatory diet is associated with systemic inflammation and reduced kidney function in elderly adults J Nutr 145 2015 729 735
47. J.F. Navarro-Gonzalez, C. Mora-Fernandez, M. Muros, H. Herrera, and J. Garcia Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study Clin J Am Soc Nephrol 4 2009 1646 1654
48. K. Caglar, M.I. Yilmaz, M. Saglam, and et al. Short-term treatment with sevelamer increases serum fetuin - A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients Clin J Am Soc Nephrol 3 2008 61 68
49. J.F. Navarro-Gonzalez, C. Mora-Fernandez, F.M. Muros de, J. Donate-Correa, V. Cazana-Perez, and J. Garcia-Perez Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients Clin J Am Soc Nephrol 6 2011 2272 2279
50. A.N. Friedman, S.M. Moe, S.M. Perkins, Y. Li, and B.A. Watkins Fish consumption and omega-3 fatty acid status and determinants in long-term hemodialysis Am J Kidney Dis 47 2006 1064 1071
51. A. Friedman, and S. Moe Review of the effects of omega-3 supplementation in dialysis patients Clin J Am Soc Nephrol 1 2006 182 192
52. X. Huang, P. Stenvinkel, A.R. Qureshi, and et al. Clinical determinants and mortality predictability of stearoyl-CoA desaturase-1 activity indices in dialysis patients J Intern Med 273 2013 263 272
53. X. Huang, P. Stenvinkel, A.R. Qureshi, and et al. Essential polyunsaturated fatty acids, inflammation and mortality in dialysis patients Nephrol Dial Transplant 27 2012 3615 3620
54. P.C. Calder n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases Am J Clin Nutr 83 6 Suppl 2006 1505S 1519S
55. X. Huang, P. Sjogren, J. Arnlov, and et al. Serum fatty acid patterns, insulin sensitivity and the metabolic syndrome in individuals with chronic kidney disease J Intern Med 275 2014 71 83
56. X. Huang, B. Lindholm, P. Stenvinkel, and J.J. Carrero Dietary fat modification in patients with chronic kidney disease: n-3 fatty acids and beyond J Nephrol 26 2013 960 974
57. H.J. Anders, K. Andersen, and B. Stecher The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease Kidney Int 83 2013 1010 1016
58. A. Aguilera, L. Gonzalez-Espinoza, R. Codoceo, and et al. Bowel bacterial overgrowth as another cause of malnutrition, inflammation, and atherosclerosis syndrome in peritoneal dialysis patients Adv Perit Dial 26 2010 130 136
59. H. Xu, X. Huang, U. Riserus, and et al. Dietary fiber, kidney function, inflammation, and mortality risk Clin J Am Soc Nephrol 9 2014 2104 2110
60. R.J. Johnson, T. Nakagawa, L.G. Sanchez-Lozada, and et al. Sugar, uric acid, and the etiology of diabetes and obesity Diabetes 62 2013 3307 3315
61. A. Brymora, M. Flisinski, R.J. Johnson, G. Goszka, A. Stefanska, and J. Manitius Low-fructose diet lowers blood pressure and inflammation in patients with chronic kidney disease Nephrol Dial Transplant 27 2012 608 612
62. J. Himmelfarb, P. Stenvinkel, T.A. Ikizler, and R.M. Hakim The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia Kidney Int 62 2002 1524 1538
63. J. Kim, Y.N. Cha, and Y.J. Surh A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders Mutat Res 690 2010 12 23
64. S. Ruiz, P.E. Pergola, R.A. Zager, and N.D. Vaziri Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease Kidney Int 83 2013 1029 1041
65. L.F. Cardozo, L.M. Pedruzzi, P. Stenvinkel, and et al. Nutritional strategies to modulate inflammation and oxidative stress pathways via activation of the master antioxidant switch Nrf2 Biochimie 95 2013 1525 1533
66. Z.D. de, T. Akizawa, P. Audhya, and et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease N Engl J Med 369 2013 2492 2503
67. S.P. Hsu, M.S. Wu, C.C. Yang, and et al. Chronic green tea extract supplementation reduces hemodialysis-enhanced production of hydrogen peroxide and hypochlorous acid, atherosclerotic factors, and proinflammatory cytokines Am J Clin Nutr 86 2007 1539 1547
68. L. Shema-Didi, S. Sela, L. Ore, and et al. One year of pomegranate juice intake decreases oxidative stress, inflammation, and incidence of infections in hemodialysis patients: a randomized placebo-controlled trial Free Radic Biol Med 53 2012 297 304
69. J. Himmelfarb, S. Phinney, T.A. Ikizler, J. Kane, E. McMonagle, and G. Miller Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients J Ren Nutr 17 2007 296 304
70. J. Himmelfarb, T.A. Ikizler, C. Ellis, and et al. Provision of antioxidant therapy in hemodialysis (PATH): a randomized clinical trial J Am Soc Nephrol 25 2014 623 633
71. M.M. Nascimento, M.E. Suliman, M. Silva, and et al. Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study Perit Dial Int 30 2010 336 342
72. M. Tepel, M. van der Giet, M. Statz, J. Jankowski, and W. Zidek The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial Circulation 107 2003 992 995
73. J. Deng, Q. Wu, Y. Liao, D. Huo, and Z. Yang Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: a systematic review and meta-analysis Nephrology (Carlton) 17 2012 545 551
74. V. Krane, K. Winkler, C. Drechsler, J. Lilienthal, W. Marz, and C. Wanner Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis Kidney Int 74 2008 1461 1467
75. A.M. Cueto-Manzano, J.R. Angel-Zuniga, G. Ornelas-Carrillo, E. Rojas-Campos, H.R. Martinez-Ramirez, and L. Cortes-Sanabria Anti-inflammatory interventions in end-stage kidney disease: a randomized, double-blinded, controlled and crossover clinical trial on the use of pravastatin in continuous ambulatory peritoneal dialysis Arch Med Res 44 2013 633 637
76. P.M. Ridker, J. MacFadyen, M. Cressman, and R.J. Glynn Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the use of statins in prevention-an intervention trial evaluating rosuvastatin) trial J Am Coll Cardiol 55 2010 1266 1273
77. J.R. Stubbs, A. Idiculla, J. Slusser, R. Menard, and L.D. Quarles Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD J Am Soc Nephrol 21 2010 353 361
78. P.J. Matias, C. Jorge, C. Ferreira, and et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters Clin J Am Soc Nephrol 5 2010 905 911
79. T. Ogawa, A. Kyono, M. Sato, H. Sugimoto, K. Otsuka, and K. Nitta Vitamin D receptor agonist supplementation and suppression of inflammation may have advantage for all-cause mortality in hemodialysis patients Clin Exp Nephrol 16 2012 779 785
80. J.L. Gamboa, M. Pretorius, D.R. Todd-Tzanetos, and et al. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis J Am Soc Nephrol 23 2012 334 342
81. A. Merino, M.A. Alvarez-Lara, R. Ramirez, J. Carracedo, A. Martin-Malo, and P. Aljama Losartan prevents the development of the pro-inflammatory monocytes CD14+CD16+ in haemodialysis patients Nephrol Dial Transplant 27 2012 2907 2912
82. Y. Morishita, S. Hanawa, J. Chinda, O. Iimura, S. Tsunematsu, and E. Kusano Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension Hypertens Res 34 2011 308 313
83. M.I. Yilmaz, J. Axelsson, A. Sonmez, and et al. Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria Clin J Am Soc Nephrol 4 2009 535 541
84. D.I. Swerdlow, M.V. Holmes, K.B. Kuchenbaecker, and et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis Lancet 379 2012 1214 1224
85. A.M. Hung, C.D. Ellis, A. Shintani, C. Booker, and T.A. Ikizler IL-1beta receptor antagonist reduces inflammation in hemodialysis patients J Am Soc Nephrol 22 2011 437 442
86. J.S. Smolen, A. Beaulieu, A. Rubbert-Roth, and et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial Lancet 371 2008 987 997
87. Available at: https://clinicaltrials.gov/ct2/show/NCT01594333. 2015. Ref Type: Generic. Accessed 8.03.2015.
88. Available at: http://www.thecantos.org/cantos-summary.html. 2015. Ref Type: Generic. Accessed 8.03.2015.
89. L. Gonzalez-Espinoza, E. Rojas-Campos, M. Medina-Perez, P. Pena-Quintero, B. Gomez-Navarro, and A.M. Cueto-Manzano Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial Nephrol Dial Transplant 27 2012 2023 2028
90. J.J. Carrero, S.H. Park, J. Axelsson, B. Lindholm, and P. Stenvinkel Cytokines, atherogenesis, and hypercatabolism in chronic kidney disease: a dreadful triad Semin Dial 22 2009 381 386